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Background
Advances in tissue characterization with late gadolinium
enhancement (LGE) by cardiovascular magnetic reso-
nance (CMR) have highlighted the importance of myo-
cardial fibrosis (MF) in hypertrophic cardiomyopathy
(HCM) by confirming that its presence and extent pre-
dicts adverse outcomes. Despite of the identification of
several genes related to HCM, few studies have investi-
gated the association between genotype and MF. In this
study, we sought to investigate the relationship between
two most common gene mutations in HCM and the
extension of MF by LGE.
Methods
We retrospectively analyzed 57 patients with HCM and
genetically positive for MYBPC3 or MYH7. All patients
had CMR examination at 1.5 T MRI system (Philips
Achieva). All patients underwent cine-MR with SSFP
sequence for left ventricle function evaluation and late
gadolinium enhancement for myocardial fibrosis detec-
tion. Myocardial fibrosis was measured by a threshold-
ing technique above normal myocardium. Left vnetricle
ejection fraction, mass and septum thickness were also
calculated. All analyses were performed using CVi42
software (Circle CVi, Calgary, CA). HCM patients
underwent clinical genetic testing on lymphocyte-
derived DNA. Genes were sequenced through a stan-
dard Sanger sequencing protocol. Here we have only
analyzed patients in which a causal mutation was identi-
fied in either MYBPC3 or MYH7.
Fisher exact test, t test and Mann Whitney test when
appropriate using Stata 12.
Results
The MYBPC3 gene mutation was present in 24 patients
(42.1%) and the MYH7 in 33 patients (57.8%). The
majority of the patients was male in both subgroups,
66.6% and 63.4%, respectively, and the mean age was
similar (36.5 vs 37.2). Myocardial dysfunction was rare
in this study, with only two patients presenting LV dys-
function (40% and 45%). Other characteristics were
similar between groups (Table 1). There was no differ-
ence in the MF extent between genetically positive
HCM patients with MYBPC3 and MYH7 gene muta-
tions (11.0% ± 2.39 vs 11.0 ± 1.44, p=0.38) (Figure 1a).
Figure 1b shows two short axis of LGE of patients with
MYBPC3 (panel A) and MYH7 (panel B) mutations.
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Table 1 Clinical and CMR characteristics of patients with
HCM and genetically positive for MYBPC3 or MYH7.
All (n=57) MYBPC3 MYH7 P-value
Age, years ± SD 36.8 ± 12.3 36.5 ± 12.2 37.2 ± 12.6 0.84
Male, n (%) 37 (64.9) 16 (66.6) 21 (63.4) 0.64
LVEF, % ± SD 71.1 ± 10.9 72.9 ± 8.5 69.6 ± 12.5 0.53
LV mass, g ± SD 207.5 ± 70.4 216.7 ± 72.9 202.2 ± 69.8 0.54
Thickness, mm ± SD 23.9 ± 6.9 22.7 ± 1.69 25.1 ± 1.24 0.24
Fibrosis (%) 11.0 ± 9.7 11.0 ± 2.39 11.0±1.44 0.38
Fibrosis, g ± SD 21.6 ± 21.0 21.4 ± 25.3 21.7 ± 17.8 0.47
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Conclusions
In our group of HCM patients, MYBPC3 and MYH7
gene mutations subgroups had similar phenotype
regarding the extent of the myocardial fibrosis measured
by late gadolinium enhancement CMR.
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